Business
fromFast Company
1 week agoNovo Nordisk to acquire Akero Therapeutics for its experimental liver disease drug
Novo Nordisk will acquire Akero Therapeutics for up to $5.2 billion to add experimental MASH drug efruxifermin and accelerate growth under CEO Mike Doustdar.